Published 09/26/2024 2:11:34 p.m.

WAVE trial reports Wrapsody superiority over standard PTA - Interventional News

Summary by Interventional News

Mahmood Razavi presenting at CIRSE 2024 Six-month results of the WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial have reported superior target lesion primary patency (TLPP) with Wrapsody (Merit Medical) cell-impermeable endoprosthesis (CIE) when compared to percutaneous transluminal angioplasty (PTA). These data were presented by Mahmood Razavi (St Joseph Heart & Vascular Center, Orange, USA) during a FIRST@CIRSE session at the Cardi…

0 Articles

0 Articles

All

Left

Center

Right

Interventional News

WAVE trial reports Wrapsody superiority over standard PTA - Interventional News

Mahmood Razavi presenting at CIRSE 2024 Six-month results of the WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial have reported superior target lesion primary patency (TLPP) with Wrapsody (Merit Medical) cell-impermeable endoprosthesis (CIE) when compared to percutaneous transluminal angioplasty (PTA). These data were presented by Mahmood Razavi (St Joseph Heart & Vascular Center, Orange, USA) during a FIRST@CIRSE session at the Cardi…

09/26/2024 2:11:34 p.m.

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center0Last Updated09/26/2024 3:39:06 p.m.Bias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics

Trending Topics

Donate Privacy Policy Manage Cookies Terms and Conditions

© 2024 Snapwise Inc